The dosing and administration of Cibinqo
Cibinqo is an oral janus kinase 1 (JAK1) inhibitor that contains the active ingredient, abrocitinib.1
Your doctor will prescribe Cibinqo for you if they think you will benefit from it. Read more on how to take Cibinqo below.
- If you have any questions, please consult your doctor for further information.
How should I take Cibinqo?
Recommended starting dose in:
200
mg *
once daily
*Patients ≥18 years of age, including those who are not at higher risk of certain medical conditions, or had an inadequate response to 100 mg once daily1,2
OR
100
mg †
once daily
†Adult patients who are at higher risk of certain medical conditions, eg, blood clots in the veins, major adverse cardiovascular event, and cancer, or ≥65 years of age1,2
The lowest effective dose for maintenance should be considered.1
- Can be taken with or without food at approximately the same time each day1
If you experience nausea, taking Cibinqo with food may help1
- Can be used with or without medicated topical therapies1
- Should be swallowed whole with water1
- Should not be split, crushed or chewed1
Who should not take Cibinqo?
If you have the following conditions, you should not take Cibinqo1:
- Hypersensitivity to abrocitinib or any of its excipients
- Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take Cibinqo
- Active serious systemic infections, including tuberculosis
- Severe hepatic impairment
- Pregnancy and breast-feeding
- Abnormalities in your blood test results
Your doctor will closely monitor your condition throughout your treatment.
Moreover, your doctor will evaluate your risk in taking Cibinqo and decide whether additional check-ups will be necessary during treatment.2 You should inform your doctor if you experience the following before or during treatment with Cibinqo2:
-
- Recently had or plan to have a vaccination
- This is important as certain vaccines are not recommended while using Cibinqo1–3
- Have or have had heart problems
- Have cancer or have had any cancer
- Previously had blood clots in the veins of your legs or lungs, or have an increased risk for developing this
References
- CIBINQO® (abrocitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version January 2024.
- CIBINQO® (abrocitinib) Package Leaflet: Information for the patient. Pfizer Corporation Hong Kong Limited: Version January 2024.
- Friedman MA, et al. Ann Rheum Dis 2021;80:1255-1265.